民德電子(300656.SZ):民德(麗水)擬與江蘇聯芯簽訂2.4億元6英寸晶圓代工生產線設備購買合同
格隆匯5月18日丨民德電子(300656.SZ)公佈,公司全資子公司民德(麗水)作為公司2021年向特定對象發行股票項目“碳化硅功率器件的研發和產業化項目”、“適用於新型能源供給的高端溝槽型肖特基二極管產能的提升及技術改進項目”的實施主體,為了保障募投項目順利開展,經過前期的市場調研和充分溝通,民德(麗水)擬與設備代理商江蘇聯芯簽訂6英寸晶圓代工生產線設備的購買合同,合同預估金額為2.4億元人民幣,該款項將使用募集資金支付。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.